Price
No data yet.
Social Signal Score
Analyst Ratings
24 analystsRevenue
$200.41M+131.39%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Wendy Barnes
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Employees
- 697
- Beta
- 1.60
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 0.24
Financials
Revenue
$200.41M+131.4%Net Income
$8.54M-14.7%EBITDA
$25.28M-30.5%Free Cash Flow
$80.47M+224.4%EPS (diluted)
$0.02-27.5%Shares Outstanding (diluted)
348.06M-4.0%Operating Expenses
$133.51MCash & Debt
$296.11MReturn of Capital
$1.95MRevenue by Segment (annual)
$685.09MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $796.85M | $30.44M | $0.09 |
| 2024 | $792.32M | $16.39M | $0.04 |
| 2023 | $750.26M | $-8.87M | $-0.02 |
| 2022 | $766.55M | $-32.83M | $-0.08 |
| 2021 | $745.42M | $-25.25M | $-0.06 |
| 2020 | $550.70M | $-293.62M | $-1.07 |
| 2019 | $388.22M | $66.05M | $0.12 |
| 2018 | $249.52M | $43.79M | $0.12 |
| 2017 | $157.24M | $8.84M | $0.02 |
| 2016 | $99.38M | $-7.77M | $-0.02 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.13
- Implied price
- $4.02
- Return from $3.28
- 4.1% a year
To earn 15.0% a year on these assumptions you'd need to buy at $2.00 — -39.1% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 22 | 27 | 32 | 37 | 42 |
|---|---|---|---|---|---|
| -2.0% | -12.3% | -8.7% | -5.5% | -2.7% | -0.2% |
| 3.0% | -7.9% | -4.0% | -0.7% | 2.2% | 4.9% |
| 8.0% | -3.4% | 0.7% | 4.1% | 7.2% | 10.0% |
| 13.0% | 1.1% | 5.3% | 9.0% | 12.2% | 15.0% |
| 18.0% | 5.6% | 10.0% | 13.8% | 17.1% | 20.1% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
90-25.00%Social Signal Score
Mentions (4)
- Newsreuters.com·7d ago·Negative
Amazon, GoodRx target US prescription subscribers as health insurance coverage slips Amazon.com , GoodRx and other companies offering online subscriptions that charge a flat fee for prescription drugs and other health services are reaping the benefits of Americans looking to combat rising costs and dwindling health insurance options.
View source ↗ - Newspymnts.com·31d ago·Positive
GoodRx Covers Whole Households and Pets in New Prescription Plan Prescription platform GoodRx has launched a new plan that covers a primary member and up to four dependents, including children, adult family members and pets, the company said in a Thursday (Sept. 3) press release.
View source ↗ - Newsreuters.com·33d ago·Negative
GoodRx offers health subscription for families, to launch as employee benefit in 2027 GoodRx, a prescription drug savings site, announced on Thursday a family healthcare subscription for access to common medical services and over 250 medications, and it plans to launch the program as part of employer health benefits in 2027.
View source ↗ - Newsseekingalpha.com·55d ago·Positive
GoodRx: Direct Brand Launches And New Subscription Plans Are Offering Hope GoodRx has rebounded from $2.50 per share, showing renewed growth momentum and improved consumer traction. New offerings have contributed to GDRX's recent positive developments, but the stock's rapid appreciation reflects these improvements. I remain marginally more positive, yet GDRX still presents considerable risk, warranting a continued neutral rating.
View source ↗
Earnings
Tue, Nov 3(in 4 weeks)
Consensus estimate $0.08 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$0.08 vs $0.08beat
- Wed, May 6$0.07 vs $0.07beat
- Wed, Feb 25$0.09 vs $0.09beat
- Tue, Nov 4$0.08 vs $0.09miss
- Wed, Aug 6$0.09 vs $0.10miss
- Wed, May 7$0.09 vs $0.09beat
Estimates and results for GDRX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by GDRX officers and directors.
- Bought
- —
- Sold
- $8.1m
0 trades
13 trades
- Francisco Partners Iv, L.p.sold
- Francisco Partners Iv, L.p.sold
- Francisco Partners Iv, L.p.sold
- Francisco Partners Iv, L.p.sold
- Francisco Partners Iv, L.p.sold
- Francisco Partners Iv, L.p.sold
- Francisco Partners Iv, L.p.sold
- Francisco Partners Iv, L.p.sold
87 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Anthony Gonzalezhouse · OH16 · disclosed Apr 23, 2021 (29d later)Buy$100,001 - $250,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.